Form 4: Trevi Therapeutics Executive Exercises Stock Options and Acquires Shares

Christopher Galletta, a key executive at Trevi Therapeutics, exercised stock options and acquired shares, increasing his holdings in the company.

Summary

• Christopher Galletta, the Controller and Principal Accounting Officer at Trevi Therapeutics, exercised stock options to acquire 15,000 shares of common stock at a price of $0.511 per share on December 13, 2024.
• This transaction increased his direct holdings to 19,935 shares, which includes 4,935 shares purchased through the company's employee stock purchase plan.
• The stock options were granted on February 11, 2022, and vested over time, with the remaining shares vesting monthly until February 11, 2026.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It reports a routine transaction by an executive, which is neither particularly positive nor negative for the company's outlook.

Positives

• The exercise of stock options by a key executive can be seen as a positive sign of confidence in the company's future prospects.
• The increase in share ownership by an executive aligns their interests with those of the shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option exercises are a common form of executive compensation in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of the options is typical, with a portion vesting initially and the remainder vesting over a period of time.
• The price of the stock options is based on the market price at the time of grant, which is standard practice.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows an executive's confidence in the company.

Key Dates

Keywords

stock options, insider trading, share acquisition, executive compensation, common stock, Trevi Therapeutics, TRVI